|
1) Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med. 1982; 306: 1018-22
|
|
|
|
2) Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anti-coagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001; 285: 2370-5
|
|
|
|
|
3) Inoue H, Fujiki A, Origasa H, et al. Prevalence of atrial fibrillation in the general population of Japan. Int J Cardiol. 2009; 137: 102-7
|
|
|
|
|
|
4) Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008; 358: 2678-87
|
|
|
|
|
|
5) Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med. 2000; 342: 913-20
|
|
|
|
|
|
6) Nattel S, Li D. Ionic remodeling in the heart: pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res. 2000; 87: 440-7
|
|
|
|
|
|
7) Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation. 1995; 92: 1954-68
|
|
|
|
|
|
8) Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002; 54: 230- 46
|
|
|
|
|
|
9) The CONSENSUS trial study group. Effects of enalapril on mortality insevere congestive heart failure. Results of the cooperative northscandinavian enalapril survival study (CONSENSUS). N Engl J Med. 1987; 316: 1429-35
|
|
|
|
|
|
10) The SOLVD investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325: 293-302
|
|
|
|
|
|
11) Fletcher RD, Cintron GB, Johnson G, et al. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group. Circulation. 1993; 87: VI49-55
|
|
|
|
|
|
12) Sogaard P, Gotzsche CO, Ravkilde J, et al. Ventricular arrhythmias in the acute and chronic phases after acute myocardial infarction. Effect of intervention with captopril. Circulation. 1994; 90: 101-7
|
|
|
|
|
|
13) Budaj A, Cybulski J, Cedro K, et al. Effects of captopril on ventricular arrhythmias in the early and late phase of suspected acute myocardial infarction. Randomized, placebo- controlled substudy of ISIS-4. Eur Heart J. 1996; 17: 1506- 10
|
|
|
|
|
|
14) Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation. 2003; 107: 2926-31
|
|
|
|
|
|
15) Wachtell K, Lehto M, Gerdts E, et al. Angiotensin-II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005; 45: 712-9
|
|
|
|
|
|
16) Pedersen OD, Bagger H, Kober L, et al. Trandopril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999; 100: 376-80
|
|
|
|
|
|
17) Pizzetti F, Turazza FM, Franzosi MG, et al. Incidence and prognostic significance of atrial firbrillation in acute myocardialinfarction: the GISSI-3 data. Heart. 2001; 86: 527-32
|
|
|
|
|
|
18) Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005; 149: 548-57
|
|
|
|
|
|
19) Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006; 152: 86-92
|
|
|
|
|
|
20) Schmieder RE, Kjeldsen SE, Julius S, et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens. 2008; 26: 403-11
|
|
|
|
|
|
21) Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002; 106: 331-6
|
|
|
|
|
|
22) Yin Y, Dalal D, Liu Z, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J. 2006; 27: 1841-6
|
|
|
|
|
|
23) Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol. 2006; 47: 46-50
|
|
|
|
|
|
24) Tveit A, Grundvold I, Olufsen M, et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol. 2007; 120: 85-91
|
|
|
|
|
|
25) The GISSI-AF investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009; 360: 1606-17
|
|
|
|
|
|
26) Yamashita T, Ogawa S, Aizawa Y, et al; J-RHYTHM II Investigators. Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension. Circ J. 2006; 70: 1318-21
|
|
|
|
|
27) Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet. 2007; 369: 1208-19
|
|
|
|
|
|
28) L'Allier PL, Ducharme A, Keller PF, et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol. 2004; 44: 159-64
|
|
|
|
|
|
29) Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation. 2000; 101: 2612-7
|
|
|
|
|
|
30) Kumagai K, Nakashima H, Urata H. Effects of angiotensin II type 1 receptor antagonism on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol. 2003; 41: 2197- 204
|
|
|
|
|
|
31) Bainbridge FA. The influence of venous filling upon the rate of the heart. J Physiol. 1915; 24: 65-84
|
|
|
|
|
|
32) Sasaki N, Mitsuiye T, Wang Z, et al. Increase of the delayed rectifier K＋ and Na＋-K＋pump currents by hypotonic solutions in guinea pig cardiac myocytes. Circ Res. 1994; 75: 887-95
|
|
|
|
|
|
33) Wang Z, Mitsuiye T, Noma A. Cell distension-induced increase of the delayed rectifier K＋ current in guinea pig ventricular myocytes. Circ Res. 1996; 78: 466-74
|
|
|
|
|
|
34) Malhotra R, Sadoshima J, Brosius FC 3rd, et al. Mechanical stretch and angiotensin II differentially upregulate the renin-angiotensin system in cardiac myocytes in vitro. Circ Res. 1999; 85: 137-46
|
|
|
|
|
|
35) Zou Y, Akazawa H, Qin Y, et al. Mechanical stress activates angiotensin II type 1receptor without the involvement of angiotensin II. Nat Cell Biol. 2004; 6: 499-506
|
|
|
|
|
|
36) Yasuda N, Miura S-I, Akazawa H, et al. Conformational switch of angiotensin II type1 receptor underlying mechanical stress-induced activation. EMBO Rep. 2008; 9: 179-86
|
|
|
|
|
|
37) Zankov DP, Toyoda F, Omatsu-Kanbe M, et al. Angiotensin II type 1 receptor mediates partially hyposmotic-induced increase of IKs current in guinea pig atrium. Pflugers Arch. 2009; 458: 837-49
|
|
|
|
|